Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.44 |
| ▸ | ACACB | O00763 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | BCR | P11274 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12006767 | 1.00 | PRCP (0.44) | PRCPACACBGAAHPGDSMN1; SMN2 | |
| SCHEMBL12004859 | 1.00 | PRCP (0.44) | PRCPACACBGAAHPGDSMN1; SMN2 | |
| SCHEMBL12006263 | 0.94 | ACACB (0.40) | PRCPACACBABL1BCRKCNH2 | |
| SCHEMBL12005612 | 0.93 | ABL1 (0.39) | PRCPACACBGAAHPGDABL1 | |
| SCHEMBL12004865 | 0.81 | ABL1 (0.38) | ABL1BCR | |
| SCHEMBL12005013 | 0.78 | ABL1 (0.41) | ABL1BCR | |
| SCHEMBL12005011 | 0.78 | ABL1 (0.41) | ABL1BCR | |
| SCHEMBL12006296 | 0.78 | ABL1 (0.41) | ABL1BCR | |
| SCHEMBL12005623 | 0.77 | ABL1 (0.36) | ABL1BCR | |
| SCHEMBL12019742 | 0.77 | ABL1 (0.40) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045496-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| EP-2678342-B1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-20140309219-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2014-10-16 | — | — | US | disclosed |
| US-8791107-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309219-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | PRCP 3781/4885ACACB 3850/4885GAA 3401/4885 |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | PRCP 3781/4885ACACB 3850/4885GAA 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.